ARTICLE | Product Development
Interception inception
What Janssen hopes to achieve with first disease interception trial in Type I diabetes
August 22, 2016 7:00 AM UTC
The first clinical trial to come from the Janssen Research & Development LLC's Disease Interception Accelerator will move upstream from the way Type I diabetes is treated today, even if it doesn't directly prevent the disease, and help parent company Johnson & Johnson build a new hypothesis about how to prevent or delay its onset.
Janssen is already exploring disease interception within its core therapeutic areas, and previously told BioCentury that it plans to begin a trial to intercept inflammatory bowel disease (IBD) in 2017. ...